

The early days 1908-1929

1910  
3 employees

1914  
Operations in Sweden initiated

1926  
80 employees

1939-40  
200+ employees

Entering biotech 1930-1984

1908

1909

1912

1917

1923-25

1930

1936

1939-40

1945

1946-48

1949-51

Pharmacists Anton Antons and August Kongsted receive royal privilege from King Frederik VIII to operate LEO Pharmacy, (Løveapoteket, originally founded in 1620), in Copenhagen, Denmark, and establish LEO Pharma.



August Kongsted



Anton Antons

LEO Pharmacy establishes a bacteriological and pharmacophysiological laboratory.

Here, the production of sterile and standardized preparations is initiated, and an inhalatorium for respiratory patients is established.



LEO Pharma's first location in Copenhagen, Denmark

Albyl® is launched and remains the most popular painkiller in Denmark for decades.



The original LEO Pharma logo is inspired by the Assyrian lions found in Nebuchadnezzar's palace in Babylon

In the newly established laboratories Dr. Marie Krogh standardises digitalis, making Digisolvin LEO® is the first Danish drug to be exported.



Waiting room in the inhalatorium situated above the LEO Pharmacy

LEO Pharma initiates insulin production and finances the development and production of insulin in the 1920s.

In 1925, the insulin production is transferred to the independent Nordisk Insulinlaboratorium.



LEO Pharma develops a number of hormone products.

Some hormones are extracted from the urine of pregnant women.



LEO Pharma staff collects urine on pushbikes

Heparin extraction method is developed.



Bottles being filled at LEO Pharma

Heparin® is launched.

August Kongsted passes away. His son-in-law Knud Abildgaard, is appointed CEO of LEO Pharma.

LEO Pharma's price list now contains approx. 230 branded products.



August Kongsted 1870-1939

LEOPenicillin® is launched.

LEO Pharma is the first company outside of the UK and the US to manufacture penicillin.

The new life-saving drug, is considered a medical miracle.



Penicillin production plants are established under licence in Italy, Spain and France.

The first bricks for LEO Pharma's new headquarters are laid in Ballerup, Denmark.

LEO Pharma starts export of pharmaceutical products.

Protaminsulphat LEO® is launched in 1951.

From 1949 to 1959, LEO Pharma moves production to the new headquarters in Ballerup, Denmark.



LEO Pharma's head quarters in Ballerup, Denmark



1958  
Operations in France, Holland, Ireland & Greece initiated

1960  
Operations in the UK initiated & new operations initiated in Sweden

1958  
2500 employees

1962  
Operations in Norway initiated

1979  
Operations in the Middle East initiated

1977  
Operations in Belgium initiated

1983  
Operations in Canada initiated

1988  
Operations in Poland & Asia initiated

Global expansion 1985-2008

1956

1958

1962

1971

1973

1976

1978

1984

1985

1986

1987

LEO Pharma's logo is registered as the official trademark.



Rontyl® is launched.



In 1958, at the 50<sup>th</sup> anniversary of the company, Abildgaard is given a lion cub. The lion is donated to the Copenhagen Zoo.



Fucidin® is launched.


Fucidin® is based on fusidic acid, a new antibiotic substance derived from the fungus *Fusidium coccineum*, discovered by LEO Pharma scientists in 1959.

Pondocillin® is launched.

The next new generation of penicillins is launched.



LEO Pharma research into vitamin D analogues begins.




LEO Pharma's Heparin production plant in Esbjerg, Denmark is established.

One-Alpha® is launched.

The LEO Foundation is established.



The D vitamin analogue, calcipotriol, is synthesized.



Fucidin® H is launched.

Knud Abildgaard passes away.


LEO Pharma is now fully owned by the LEO Foundation.



Knud Abildgaard 1901-1986

Fucicort® is launched.





**1990**  
Operations in Finland initiated

**1992**  
Operations in Germany initiated

**1995**  
Operations in Spain initiated

**1997**  
Operations in Portugal initiated

**1991**  
Operations in Switzerland initiated

**1994**  
4,250 employees worldwide

**1996**  
Operations in Austria initiated

**2001**  
Operations in Morocco initiated

**2002**  
Operations in Algeria initiated

**2003**  
Operations in Tunisia initiated

**2009**  
Operations in the US, China & Australia initiated

**2010**  
Operations in Brazil, Japan & Mexico initiated

**2011**  
Operations in Italy, Turkey & South Korea initiated

**Focus on dermatology**

1991

1994

1998

2000

2001

2002

2003

2005

2008

2009

2011

Daivonex®/ Dovonex® and Innohep® are launched.



Daivonex® is awarded the prestigious Belgian pharmaceutical award Prix Galien.



An R&D facility state-of-the-art facilities is built in Ballerup.




LEO Pharma R&D facilities in Ballerup, Denmark

LEO Pharma is awarded an environmental award, Københavns Amt Miljøpris as well as King Frederik IX's Award for Excellence in Export.



LEO Pharma manages to combine two unmixable compounds: calcipotriol and betamethasone dipropionate, and Daivobet®/ Dovobet® is launched.



LEO Pharma changes the Danish company name from Løvens Kemiske Fabrik to LEO Pharma.



Daivobet®/ Dovobet® receives the Confederation of Danish Industries' Product Award.

Daivobet®/ Dovobet® is approved in the US under the name Taclonex®.

Xamiol® is launched. Taclonex Scalp® Topical Suspension approved in the US.

LEO Pharma celebrates its 100years anniversary.



LEO Pharma reacquires marketing rights in the US.

LEO Pharma introduces its new mission: 'We help people achieve healthy skin'.



2012-13

Picato® is launched.

2014

LEO Pharma Open Innovation is established: a collaborative space created to explore partnerships and the latest research using some of LEO Pharma's unique scientific resources.

[openinnovation.leo-pharma.com](http://openinnovation.leo-pharma.com)

2015

LEO Pharma acquires dermatology portfolio from Astellas.

LEO Pharma establishes LEO Innovation Lab: pursuing digital solutions to help people with skin diseases.



2016

Enstilar® is launched.

LEO Pharma enters biologics through strategic partnership with AstraZeneca.

LEO Pharma establishes LEO Science & Tech Hub in Boston: exploring cutting-edge science and technology opportunities with relevance to dermatology.

**LEOSCIENCE & TECHHUB**

2017

2017  
LEO Pharma builds R&D hub in China.

Kyntheum®, LEO Pharma's first biologic treatment for psoriasis, is launched

LEO Pharma passes revenue of more than DKK 10 billion for the first time.

2018

2018  
5,528 employees

LEO Pharma acquires Bayer's prescription dermatology business.

2019

2019  
5,820 employees

LEO Pharma breaks ground for the new Fucidin® Active Pharmaceutical Ingredient production plant in Ballerup, Denmark.



Visualization of LEO Pharma's new API production plant in Ballerup, Denmark

2020

2020  
5,955 employees

LEO Pharma enters license agreement with Oneness Biotech and Microbio Shanghai for FB825, an atopic dermatitis and asthma drug candidate.

2021

Nordic Capital invests in LEO Pharma and becomes an active minority owner and partner to the LEO Foundation.

Adtralza® is launched

